<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426386</url>
  </required_header>
  <id_info>
    <org_study_id>000009</org_study_id>
    <secondary_id>2011-000633-36</secondary_id>
    <nct_id>NCT01426386</nct_id>
  </id_info>
  <brief_title>A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment</brief_title>
  <official_title>A Randomised, Controlled, Assessor-blind, Parallel Groups, Multi-national, Multi-centre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Women Undergoing an ART Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the effects of several doses of FE 999049 in women undergoing
      IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes Retrieved</measure>
    <time_frame>Day of oocyte retrieval (up to Day 18 after start of stimulation)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Size of Follicles During Stimulation</measure>
    <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
    <description>Follicular volume at end of stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Profile</measure>
    <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
    <description>Estradiol at end of stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IMP Dose</measure>
    <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fertilised Oocytes</measure>
    <time_frame>Day 1 after insemination</time_frame>
    <description>An oocyte with 2 pronuclei was regarded as correctly fertilised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Quality of Blastocysts on Day 5</measure>
    <time_frame>Day 5 after oocyte retrieval</time_frame>
    <description>Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy With Fetal Heart Beat Rate</measure>
    <time_frame>5-6 weeks after transfer</time_frame>
    <description>Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Adverse Events</measure>
    <time_frame>From signing informed consent form until end of trial visit (up to 5 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>5.2 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6.9 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.3 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12.1 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>11 µg FbM (150 IU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 999049</intervention_name>
    <arm_group_label>10.3 µg</arm_group_label>
    <arm_group_label>12.1 µg</arm_group_label>
    <arm_group_label>5.2 µg</arm_group_label>
    <arm_group_label>6.9 µg</arm_group_label>
    <arm_group_label>8.6 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal - F</intervention_name>
    <arm_group_label>11 µg FbM (150 IU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with tubal infertility, unexplained infertility, infertility related
             to endometriosis stage I/II or with partners diagnosed with male factor infertility

          -  Women eligible for IVF (in-vitro fertilisation) and/or ICSI (intracytoplasmic sperm
             injection) treatment

          -  Women aged 18-37 years

          -  Women with body mass index (BMI) of 18.5-32.0 kg/m2

        Exclusion Criteria:

          -  Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis
             stage III/IV

          -  Women with history of recurrent miscarriage

          -  Women with contraindications to controlled ovarian stimulation with gonadotropins

          -  Women with three or more controlled ovarian stimulation cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICF CUBE</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Dexeus</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>August 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2018</results_first_posted>
  <disposition_first_submitted>April 12, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 19, 2013</disposition_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 7 sites randomised subjects to the trial: 1 in Belgium, 1 in Czech Republic, 1 in Denmark and 4 in Spain.</recruitment_details>
      <pre_assignment_details>In total 334 subjects were screened. Of these, 69 were screening failures and 265 were randomised. All randomised subjects were exposed to investigational medicinal product (IMP).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FE 999049 5.2 µg</title>
          <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="P2">
          <title>FE 999049 6.9 µg</title>
          <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="P3">
          <title>FE 999049 8.6 µg</title>
          <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="P4">
          <title>FE 999049 10.3 µg</title>
          <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="P5">
          <title>FE 999049 12.1 µg</title>
          <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="P6">
          <title>GONAL-F 11 µg</title>
          <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not attend scheduled visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FE 999049 5.2 µg</title>
          <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="B2">
          <title>FE 999049 6.9 µg</title>
          <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="B3">
          <title>FE 999049 8.6 µg</title>
          <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="B4">
          <title>FE 999049 10.3 µg</title>
          <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="B5">
          <title>FE 999049 12.1 µg</title>
          <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="B6">
          <title>GONAL-F 11 µg</title>
          <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="43"/>
            <count group_id="B7" value="265"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="2.24"/>
                    <measurement group_id="B2" value="32.3" spread="3.51"/>
                    <measurement group_id="B3" value="32.8" spread="2.44"/>
                    <measurement group_id="B4" value="32.3" spread="3.21"/>
                    <measurement group_id="B5" value="32.6" spread="2.97"/>
                    <measurement group_id="B6" value="32.4" spread="3.04"/>
                    <measurement group_id="B7" value="32.7" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Oocytes Retrieved</title>
        <time_frame>Day of oocyte retrieval (up to Day 18 after start of stimulation)</time_frame>
        <population>Modified Intention-to-treat (mITT) population (all randomised and exposed subjects). This is equivalent to the Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved</title>
          <population>Modified Intention-to-treat (mITT) population (all randomised and exposed subjects). This is equivalent to the Full Analysis Set (FAS)</population>
          <units>Oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.3"/>
                    <measurement group_id="O2" value="7.9" spread="5.9"/>
                    <measurement group_id="O3" value="9.2" spread="4.6"/>
                    <measurement group_id="O4" value="10.5" spread="7.0"/>
                    <measurement group_id="O5" value="12.2" spread="5.9"/>
                    <measurement group_id="O6" value="10.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The dose-response relationship was analysed using an analysis of covariance (ANCOVA) model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on the ANCOVA model the slope of the dose-response curve was estimated. Null hypothesis: Slope of dose-response curve equal to 0 (zero)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 5% (two-sided)</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Number of oocytes retrieved as dependent variable, centre and AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factors and log(dose) as covariate</method_desc>
            <param_type>Slope of the dose-response curve</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.69</ci_lower_limit>
            <ci_upper_limit>10.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Size of Follicles During Stimulation</title>
        <description>Follicular volume at end of stimulation</description>
        <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
        <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Size of Follicles During Stimulation</title>
          <description>Follicular volume at end of stimulation</description>
          <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="7.0"/>
                    <measurement group_id="O2" value="23.0" spread="10.5"/>
                    <measurement group_id="O3" value="25.0" spread="9.2"/>
                    <measurement group_id="O4" value="27.9" spread="15.6"/>
                    <measurement group_id="O5" value="28.2" spread="9.5"/>
                    <measurement group_id="O6" value="26.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The dose-response relationship was analysed using an analysis of covariance (ANCOVA) model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on the ANCOVA model the slope of the dose-response curve was estimated. Null hypothesis: Slope of dose-response curve equal to 0 (zero)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiplicity was applied for the secondary endpoints</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Follicular volume as dependent variable, centre and AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factors and log(dose) as covariate</method_desc>
            <param_type>Slope of the dose-response curve</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.78</ci_lower_limit>
            <ci_upper_limit>15.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endocrine Profile</title>
        <description>Estradiol at end of stimulation</description>
        <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
        <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Endocrine Profile</title>
          <description>Estradiol at end of stimulation</description>
          <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3641.9" spread="2954.6"/>
                    <measurement group_id="O2" value="5221.1" spread="3378.8"/>
                    <measurement group_id="O3" value="5689.5" spread="3995.7"/>
                    <measurement group_id="O4" value="6171.8" spread="3855.9"/>
                    <measurement group_id="O5" value="6442.0" spread="3195.2"/>
                    <measurement group_id="O6" value="5750.7" spread="3709.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The dose-response relationship was analysed using an analysis of covariance (ANCOVA) model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on the ANCOVA model the slope of the dose-response curve was estimated. Null hypothesis: Slope of dose-response curve equal to 0 (zero)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiplicity was applied for the secondary endpoints</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Log(estradiol) as dependent variable, AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factor, log(dose) and log(baseline estradiol) as covariates</method_desc>
            <param_type>Slope of the dose-response curve</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IMP Dose</title>
        <time_frame>End of stimulation (up to 16 stimulation days)</time_frame>
        <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total IMP Dose</title>
          <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
          <units>µg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="11.6"/>
                    <measurement group_id="O2" value="61.9" spread="13.7"/>
                    <measurement group_id="O3" value="71.9" spread="14.1"/>
                    <measurement group_id="O4" value="81.0" spread="14.2"/>
                    <measurement group_id="O5" value="97.8" spread="22.0"/>
                    <measurement group_id="O6" value="94.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fertilised Oocytes</title>
        <description>An oocyte with 2 pronuclei was regarded as correctly fertilised</description>
        <time_frame>Day 1 after insemination</time_frame>
        <population>Subjects with oocytes retrieved</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fertilised Oocytes</title>
          <description>An oocyte with 2 pronuclei was regarded as correctly fertilised</description>
          <population>Subjects with oocytes retrieved</population>
          <units>Fertilised oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.5"/>
                    <measurement group_id="O2" value="5.4" spread="3.8"/>
                    <measurement group_id="O3" value="4.9" spread="2.7"/>
                    <measurement group_id="O4" value="6.1" spread="5.1"/>
                    <measurement group_id="O5" value="6.7" spread="3.5"/>
                    <measurement group_id="O6" value="6.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The dose-response relationship was analysed using an analysis of covariance (ANCOVA) model</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on the ANCOVA model the slope of the dose-response curve was estimated. Null hypothesis: Slope of dose-response curve equal to 0 (zero)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiplicity was applied for the secondary endpoints</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Fertilised oocytes as dependent variable, AMH strata (5.0-14.9 pmol/L and 15.0-44.9 pmol/L) as factor and log(dose) as covariate</method_desc>
            <param_type>Slope of the dose-response curve</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Quality of Blastocysts on Day 5</title>
        <description>Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher</description>
        <time_frame>Day 5 after oocyte retrieval</time_frame>
        <population>Subjects with oocytes retrieved</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Quality of Blastocysts on Day 5</title>
          <description>Number of blastocysts (total and good-quality) on Day 5 are presented. A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher</description>
          <population>Subjects with oocytes retrieved</population>
          <units>Blastocysts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total blastocysts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.7"/>
                    <measurement group_id="O2" value="3.1" spread="2.7"/>
                    <measurement group_id="O3" value="2.7" spread="2.0"/>
                    <measurement group_id="O4" value="2.8" spread="2.8"/>
                    <measurement group_id="O5" value="3.2" spread="2.2"/>
                    <measurement group_id="O6" value="3.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good quality blastocysts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.2"/>
                    <measurement group_id="O2" value="1.4" spread="1.7"/>
                    <measurement group_id="O3" value="1.2" spread="1.2"/>
                    <measurement group_id="O4" value="1.4" spread="1.5"/>
                    <measurement group_id="O5" value="1.3" spread="1.3"/>
                    <measurement group_id="O6" value="1.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy With Fetal Heart Beat Rate</title>
        <description>Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat</description>
        <time_frame>5-6 weeks after transfer</time_frame>
        <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy With Fetal Heart Beat Rate</title>
          <description>Clinical pregnancy with fetal heart beat was defined as at least one intrauterine gestational sac with fetal heart beat</description>
          <population>mITT population (all randomised and exposed subjects). This is equivalent to the FAS</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="21.6" upper_limit="52.0"/>
                    <measurement group_id="O2" value="40" lower_limit="25.7" upper_limit="55.7"/>
                    <measurement group_id="O3" value="36" lower_limit="22.4" upper_limit="52.2"/>
                    <measurement group_id="O4" value="25" lower_limit="13.2" upper_limit="40.3"/>
                    <measurement group_id="O5" value="40" lower_limit="26.4" upper_limit="55.7"/>
                    <measurement group_id="O6" value="51" lower_limit="35.5" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment groups were compared using the chi-squared test.</non_inferiority_desc>
            <p_value>0.248</p_value>
            <p_value_desc>No adjustment for multiplicity was applied for the secondary endpoints</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Adverse Events</title>
        <time_frame>From signing informed consent form until end of trial visit (up to 5 months)</time_frame>
        <population>Safety population (all randomised and exposed subjects). This is equivalent to the mITT</population>
        <group_list>
          <group group_id="O1">
            <title>FE 999049 5.2 µg</title>
            <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O2">
            <title>FE 999049 6.9 µg</title>
            <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O3">
            <title>FE 999049 8.6 µg</title>
            <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O4">
            <title>FE 999049 10.3 µg</title>
            <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O5">
            <title>FE 999049 12.1 µg</title>
            <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
          </group>
          <group group_id="O6">
            <title>GONAL-F 11 µg</title>
            <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Adverse Events</title>
          <population>Safety population (all randomised and exposed subjects). This is equivalent to the mITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing informed consent form until the end of trial visit (up to 5 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FE 999049 5.2 µg</title>
          <description>Subjects received single daily subcutaneous injections of 5.2 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="E2">
          <title>FE 999049 6.9 µg</title>
          <description>Subjects received single daily subcutaneous injections of 6.9 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="E3">
          <title>FE 999049 8.6 µg</title>
          <description>Subjects received single daily subcutaneous injections of 8.6 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="E4">
          <title>FE 999049 10.3 µg</title>
          <description>Subjects received single daily subcutaneous injections of 10.3 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="E5">
          <title>FE 999049 12.1 µg</title>
          <description>Subjects received single daily subcutaneous injections of 12.1 µg FE 999049, for a maximum of 16 days</description>
        </group>
        <group group_id="E6">
          <title>GONAL-F 11 µg</title>
          <description>Subjects received single daily subcutaneous injections of 11 µg GONAL-F, for a maximum of 16 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Compliance</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

